

The Manager  
Company Announcements Office  
ASX Limited

## Chairman's Address to EGM

**1 August 2014, ADELAIDE:** I will make a very short address at today's meeting as the reasons behind the recent capital raising are well documented in recent announcements and the SPP documents issued to shareholders in June.

Culminating in today's meeting, LBT has raised just over \$2 million dollars. This strengthens the Company's financial position to undertake the clinical trials for APAS that underpin the 510K de novo submission to the US Food and Drug Administration (the FDA). The additional funds will also allow us to commence the early prototype development of Woundvue. Woundvue is the next target product development program based on LBT's Intelligent Imaging Platform. The Board would like to thank the investors who have come forward in this capital raising and shown their support for the company's future programs. It also should be recognised that LBT Board members have themselves also directly supported the capital raising program. Details of their additional investment is of course subject to shareholder approval later in this meeting

The LBT Board would also like to recognise the support of Bell Potter Securities and in particular Anton Whitehead who has acted as our corporate adviser in this program

I would now like to turn to the agenda items for this EGM

– ENDS –

### About LBT Innovations

LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has two breakthrough products in microbiology automation: PREVI® Isola, which provides automation of culture plate streaking, and APAS®, a breakthrough in automated culture plate reading, interpretation and reporting. LBT also has a third product in development, Woundvue™, a proposed automation solution to assist in the management of chronic wounds.

LBT has an exclusive global licence agreement with French diagnostics company bioMérieux to manufacture and market PREVI® Isola. LBT receives ongoing royalty payments for PREVI Isola, which has been installed in clinical laboratories around the world. LBT's APAS® technology (the Automated Plate Assessment System) is nearing market. Based upon LBT's innovative intelligent image interpretation platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a Joint Venture with Hettich AG Switzerland to drive the commercial development and global distribution of APAS instrumentation and software products.

For more information, see [www.lbtinnovations.com](http://www.lbtinnovations.com)

### CONTACTS

LBT Innovations	Media Relations
Lusia Guthrie CEO Tel: +61 (0)8 8227 1555 E: <a href="mailto:info@lbtinnovations.com">info@lbtinnovations.com</a>	Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 E: <a href="mailto:rudim@monsoon.com.au">rudim@monsoon.com.au</a>